Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;40(4):221-229.
doi: 10.1097/HCO.0000000000001235. Epub 2025 May 14.

Anabolic-androgenic steroids among recreational athletes and cardiovascular risk

Sean Meagher  1   2 , Michael S Irwig  3 , Prashant Rao  1   2
Affiliations
Review

Anabolic-androgenic steroids among recreational athletes and cardiovascular risk

Sean Meagher et al. Curr Opin Cardiol. .

Abstract

Purpose of review: The use of androgenic anabolic steroids (AAS) is rising, particularly among recreational athletes. This review addresses growing concerns about the underrecognized cardiovascular and multiorgan consequences of chronic AAS exposure with a focus on noncompetitive populations.

Recent findings: It is well documented that AAS use enhances muscle mass and strength, but at the cost of multisystem toxicity including endocrine disruption, hepatotoxicity, and mood disorders. Emerging evidence highlights the profound cardiovascular impact of AAS use, including elevated blood pressure, adverse lipid profiles, accelerated atherosclerosis, subclinical cardiomyopathy, and increased risk of myocardial infarction and sudden cardiac death. Structural and functional cardiac abnormalities such as left ventricular hypertrophy, ventricular dysfunction, and arterial stiffness have been reported, with some changes persisting after cessation.

Summary: AAS use carries multisystem risks with evidence for adverse cardiovascular remodeling and atherogenesis. Clinicians caring for athletes using AAS should recognize patterns of AAS use and provide risk stratification, monitoring, and tapering strategies. Future research should prioritize long-term outcomes, sex-specific effects, and multidisciplinary approaches to care.

Keywords: anabolic-androgenic steroids; androgen abuse; cardiovascular risk; performance-enhancing drugs; recreational athletes.

PubMed Disclaimer

References

    1. Brown-Séquard. Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. The Lancet. 1889;134(3438):105–107. doi: 10.1016/S0140-6736(00)64118-1 - DOI
    1. Farhi P. The History Of Chemistry In Baseball. The Washington Post. https://www.washingtonpost.com/archive/style/2009/05/25/the-history-of-c.... May 25, 2009. Accessed April 6, 2025.
    1. Levine EB, Sellers AL. Testosterone in angina pectoris. Am J Med Sci. 1946;(1):7–11. - PubMed
    1. P F, Ag S. Testosterone propionate in the treatment of renal failure. Clin Sci. 1957;16(1). Accessed October 6, 2024. https://pubmed-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/13414136/ - PubMed
    1. G W, Wh M, G E. Hypopituitarism, hypogonadism, and anaemia treated with testosterone. Lancet Lond Engl. 1947;1(6454). Accessed October 6, 2024. https://pubmed-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/20239096/ - PubMed

MeSH terms